Status:
COMPLETED
Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea
Lead Sponsor:
LEO Pharma
Collaborating Sponsors:
Bayer
Conditions:
Papulopustular Rosacea
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Assessment of pharmacokinetics of Azelaic Acid Foam after repeated skin application and in comparison to Azelaic Acid gel. Assessment of safety after repeated skin application.
Eligibility Criteria
Inclusion
- diagnosis of moderate papulopustular rosacea
- free of any clinically significant disease
Exclusion
- body weight less than 50 or more than 130 kg
- clinically significant disease which could interfere with the study
Key Trial Info
Start Date :
January 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT01257919
Start Date
January 1 2011
End Date
March 1 2011
Last Update
June 9 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novum Pharmaceutical Research Services of Nevada Inc.
Las Vegas, Nevada, United States, 89121